Showing results for:

Article Cardiovascular diseases Research 20 March 2023 Free

The cost‐effectiveness of coronary calcium score‐guided statin therapy initiation for Australians with family histories of premature coronary artery disease

Expanding eligibility for statin therapy should selectively target people with subclinical atherosclerosis rather than simply lowering treatment thresholds

Prasanna Venkataraman · Amanda L Neil · Geoffrey K Mitchell · Tony Stanton · Stephen Nicholls · Andrew M Tonkin · Gerald F Watts · Thomas H Marwick

Mja2 51860
Article Infectious diseases Research 23 January 2023 Open Access

Factors associated with hospitalisations and deaths of residential aged care residents with COVID‐19 during the Omicron (BA.1) wave in Queensland

Having received three COVID-19 vaccine doses was associated with much lower likelihood of hospitalisation or death

Robert J Ellis · Cameron RM Moffatt · Luke T Aaron · Greta Beaverson · Khin Chaw · Corinne Curtis · Rhett Freeman‐Lamb · Deborah Judd · Khadija Khatry · Yee Sum Li · Terry Nash · Bonnie Macfarlane · Karen Slater · Yudish Soonarane · Mark Stickley · Satyamurthy Anuradha

Mja2 51813
Podcast Podcasts 2022 Ep 43 28 November 2022 Free

New hope for resistant hypertension, with Prof Markus Schlaich

Vol 217, Issue 11: 28 November 2022. Professor Markus Schlaich is Director of the Dobney Hypertension Centre in Perth, and Dobney Chair of Clinical Research at the University of Western Australia. His recently published research on dual endothelin antagonist aprocitentin for resistant hypertension can be found at The Lancet. His op-ed for InSight+ is free to access and can be found here. With MJA news and online editor Cate Swannell. 23 mins, 41 secs.

Professor Markus Schlaich

Professor20 Markus20 Schlaich

Subscribe to MJA email alerts

No spam, you can unsubscribe anytime you want.

By providing your information, you agree to our Terms of Use and our Privacy Policy.

Thanks for Subscribing! Tell us more

Your email updates will use your name.

Good one! Your updates are coming

Thank you for subscribing to the MJA email alerts. Receive the latest content in your inbox.